Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies

Br J Dermatol. 2010 May;162(5):1144-6. doi: 10.1111/j.1365-2133.2010.09669.x. Epub 2010 Mar 6.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents / therapeutic use*
  • Female
  • Humans
  • Psoriasis / drug therapy*
  • Treatment Failure
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Ustekinumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Ustekinumab